Outcomes and the effect of PGT-M in women with hormone-related hereditary tumor syndrome

Dingran Wang, Xueling Song, Xiaohui Zhu, Yan Li-ying, Xu Zhi, Jie Yan, Huamao Liang, Jie QiaoFrontiers in Oncology 2024 · DOI

Abstract

PGT-M results can provide important information for improving the consultation of hormone-related heritage tumor patients regarding their fertility preservation and reproductive options. Ovarian induction for women with hormone-related hereditary tumor syndrome is not associated with tumor progression.

Introduction

Women with hormone-related hereditary tumor syndromes, such as Hereditary Breast and Ovarian Cancer (HBOC) and Lynch syndrome, face a dual challenge: a significantly increased lifetime risk of malignancy and a 50% probability of transmitting pathogenic genetic variants to their children. While Preimplantation Genetic Testing for Monogenic defects (PGT-M) allows for the selection of mutation-free embryos, the process requires controlled ovarian stimulation (COS) using high doses of gonadotropins. Given the hormone-sensitive nature of tissues like the breast and endometrium, clinical concerns persist regarding whether the resulting estradiol surge might trigger tumor growth or recurrence. This study evaluates the efficacy and oncological safety of PGT-M in this high-risk population.

Materials and Methods

This retrospective study analyzed 11 women undergoing 13 IVF/PGT-M cycles at Peking University Third Hospital between 2015 and 2023. The cohort included five patients with Lynch syndrome (mutations in MLH1, MSH2, MSH6) and six with HBOC (mutations in BRCA1, BRCA2).

Table 1: Clinical characteristics and genetic profiles of the patient cohort.

The technical pipeline involved blastocyst biopsy followed by Multiple Annealing and Looping Based Amplification Cycles (MALBAC) for DNA amplification. Linkage analysis was performed using scHaplotyper software to determine carrier status, with validation via Sanger sequencing. Oncological safety was monitored through multidisciplinary follow-up (10–18 months) using imaging modalities such as TVS, MRI, CT, or colonoscopy to compare pre- and post-treatment status.

Results

The study identified a significant "genetic bottleneck," where only 28.1% (9/32) of tested embryos were found to be suitable for transfer (free of pathogenic mutations and chromosomally normal). This underscores the necessity of retrieving a sufficient number of oocytes to ensure reproductive success.

Table 3: Detailed IVF cycle parameters and reproductive outcomes for each patient.

Key findings include:

  • Oocyte Yield: A median of 13 oocytes were retrieved per patient, resulting in a median of 8 fertilized (2PN) zygotes.
  • Clinical Success: Six transfer cycles were performed, resulting in five clinical pregnancies and five live births, representing an 83% success rate.
  • Oncological Safety: Examinations 10–18 months after delivery or PGT-M revealed no new lesions or tumor progression in any of the 11 patients.

Discussion and Conclusion

The high clinical pregnancy and live birth rates suggest that the underlying hereditary conditions do not inherently impair reproductive potential once genetic selection is achieved. Furthermore, the lack of tumor progression supports the safety of short-term hormonal exposure for IVF in BRCA or Lynch carriers, adding to the growing evidence that COS may not be as dangerous for these populations as previously feared.

However, the study is limited by its small sample size and relatively short follow-up period. Future multicenter prospective studies with longer-term data (5–10 years) are necessary to definitively confirm long-term oncological safety and explore PGT-M applications in other hereditary syndromes.

Summary updated

Abstract

PGT-M results can provide important information for improving the consultation of hormone-related heritage tumor patients regarding their fertility preservation and reproductive options. Ovarian induction for women with hormone-related hereditary tumor syndrome is not associated with tumor progression.
BibTeX
@inproceedings{wang2024outcomes,
  author = {Dingran Wang and Xueling Song and Xiaohui Zhu and Yan Li-ying and Xu Zhi and Jie Yan and Huamao Liang and Jie Qiao},
  title = {{Outcomes and the effect of PGT-M in women with hormone-related hereditary tumor syndrome}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1378019},
}
Figure